Biology and treatment of myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue , 2014, Pages S65-S70

  Brioli, Annamaria ^a,b   Melchor, Lorenzo ^a   Walker, Brian A ^a   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Genetic; Intraclonal heterogeneity; Multiple myeloma; Sequential treatment; Treatment

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN;

CANCER THERAPY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLONAL VARIATION; CONFERENCE PAPER; GENETIC ANALYSIS; HUMAN; MULTIPLE MYELOMA; CLINICAL PROTOCOL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PROGNOSIS;

CLINICAL PROTOCOLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS;

EID: 84928642836     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.06.011     Document Type: Conference Paper

References (76)

1. G.J. Morgan, B.A. Walker, and F.E. Davies The genetic architecture of multiple myeloma Nat Rev Cancer 12 2012 335 348
2. P.L. Bergsagel, W.M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma Blood 106 2005 296 303
3. M.H. Bakkus, C. Heirman, I. Van Riet, B. Van Camp, and K. Thielemans Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation Blood 80 1992 2326 2335
4. P.L. Bergsagel, M. Chesi, E. Nardini, L.A. Brents, S.L. Kirby, and W.M. Kuehl Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma Proc Natl Acad Sci U S A 93 1996 13931 13936
5. M. Hallek, P.L. Bergsagel, and K.C. Anderson Multiple myeloma: increasing evidence for a multistep transformation process Blood 91 1998 3 21
6. B.A. Walker, C.P. Wardell, D.C. Johnson, and et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells Blood 121 2013 3413 3419
7. P. Broderick, D. Chubb, D. Johnson, and et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk Nat Genet 44 2012 58 61
8. T. Rasmussen, J. Haaber, I. Dahl, and et al. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma Haematologica 95 2010 1730 1737
9. E. Hurt, A. Wiestner, A. Rosenwald, and et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma Cancer Cell 5 2004 191 199
10. R. Fonseca, R.J. Bailey, G.J. Ahmann, and et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood 100 2002 1417 1424
11. M. Chesi, and P.L. Bergsagel Many multiple myelomas: making more of the molecular mayhem Hematology Am Soc Hematol Educ Program 2011 2011 344 353
12. M.A. Chapman, M.S. Lawrence, J.J. Keats, and et al. Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
13. W.J. Chng, N. Gonzalez-Paz, T. Price-Troska, and et al. Clinical and biological significance of RAS mutations in multiple myeloma Leukemia 22 2008 2280 2284
14. R. Fonseca, P.L. Bergsagel, J. Drach, and et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 23 2009 2210 2221
15. A. Zingone, C.M. Cultraro, D.M. Shin, and et al. Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms Leukemia 24 2010 1171 1178
16. M. Chesi, and P.L. Bergsagel Molecular pathogenesis of multiple myeloma: basic and clinical updates Int J Hematol 97 2013 313 323
17. T. Steinbrunn, T. Stuhmer, S. Gattenlohner, and et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival Blood 117 2011 1998 2004
18. A. Zingone, and W.M. Kuehl Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma Semin Hematol 48 2011 4 12
19. Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma [published online January 13, 2014]. Leukemia.
20. T. Holien, T.K. Vatsveen, H. Hella, A. Waage, and A. Sundan Addiction to c-MYC in multiple myeloma Blood 120 2012 2450 2453
21. A. Gabrea, M.L. Martelli, Y. Qi, and et al. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors Genes Chromosomes Cancer 47 2008 573 590
22. B.A. Walker, P.E. Leone, L. Chiecchio, and et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value Blood 116 2010 e56 e65
23. H. Avet-Loiseau, F. Gerson, F. Magrangeas, and et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors Blood 98 2001 3082 3086
24. W.J. Chng, G.F. Huang, T.H. Chung, and et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma Leukemia 25 2011 1026 1035
25. B. Walker, C. Wardell, A. Brioli, and et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients Blood Cancer J 2014 4
26. C.M. Annunziata, R.E. Davis, Y. Demchenko, and et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma Cancer Cell 12 2007 115 130
27. J.J. Keats, R. Fonseca, M. Chesi, and et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma Cancer Cell 12 2007 131 144
28. R. Elgueta, V.C. de Vries, and R.J. Noelle The immortality of humoral immunity Immunol Rev 236 2010 139 150
29. A. Dib, A. Gabrea, O.K. Glebov, P.L. Bergsagel, and W.M. Kuehl Characterization of MYC translocations in multiple myeloma cell lines J Natl Cancer Inst Monogr 2008 25 31
30. L. Lode, M. Eveillard, V. Trichet, and et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma Haematologica 95 2010 1973 1976
31. H. Avet-Loiseau, C. Li, F. Magrangeas, and et al. Prognostic significance of copy-number alterations in multiple myeloma J Clin Oncol 27 2009 4585 4590
32. J.D. Shaughnessy Jr., F. Zhan, B.E. Burington, and et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Blood 109 2007 2276 2284
33. H. Avet-Loiseau, M. Attal, P. Moreau, and et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood 109 2007 3489 3495
34. K.D. Boyd, F.M. Ross, L. Chiecchio, and et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial Leukemia 26 2012 349 355
35. S. Kumar, R. Fonseca, R.P. Ketterling, and et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics Blood 119 2012 2100 2105
36. A. Brioli, F.M. Ross, M.F. Kaiser, and et al. The impact of thalidomide maintenance therapy varies dependent upon biological risk grouping ASH Annual Meeting Abstracts 120 2012 199
37. C. Pawlyn, L. Melchor, E.M. Boyle, and et al. Co-existent hyperdiploidy does not abrogate the poor prognosis associated with adverse cytogenetics in myeloma ASH Annual Meeting Abstracts 2013 (abstract 529)
38. H. Avet-Loiseau, B. Durie, M. Cavo, and et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project Leukemia 27 2013 711 717
39. F. Zhan, Y. Huang, S. Colla, and et al. The molecular classification of multiple myeloma Blood 108 2006 2020 2028
40. A. Broyl, D. Hose, H. Lokhorst, and et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients Blood 116 2010 2543 2553
41. B. Nair, F. van Rhee, J. Shaughnessy, and et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance Blood 115 2010 4168 4173
42. O. Decaux, L. Lodé, F. Magrangeas, and et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome J Clin Oncol 26 2008 4798 4805
43. N.J. Dickens, B.A. Walker, P.E. Leone, and et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome Clin Cancer Res 16 2010 1856 1864
44. G.J. Morgan, F.E. Davies, W.M. Gregory, and et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results Haematologica 97 2012 442 450
45. A. Brioli, K.D. Boyd, M.F. Kaiser, and et al. Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy Br J Haematol 161 2013 291 294
46. B.A. Walker, C.P. Wardell, L. Melchor, and et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms [published online July 2, 2013] Leukemia 28 2014 384 390
47. B.A. Walker, C.P. Wardell, L. Melchor, and et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma Blood 120 2012 1077 1086
48. J.J. Keats, M. Chesi, J.B. Egan, and et al. Clonal competition with alternating dominance in multiple myeloma Blood 120 2012 1067 1076
49. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group Br J Haematol 121 2003 749 757
50. F. Magrangeas, H. Avet-Loiseau, W. Gouraud, and et al. Minor clone provides a reservoir for relapse in multiple myeloma Leukemia 27 2013 473 481
51. T.J. Ley, E.R. Mardis, L. Ding, and et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome Nature 456 2008 66 72
52. W. Lee, Z. Jiang, J. Liu, and et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient Nature 465 2010 473 477
53. C.C. Maley, P.C. Galipeau, J.C. Finley, and et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma Nat Genet 38 2006 468 473
54. F. Su, W.D. Bradley, Q. Wang, and et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation Cancer Res 72 2012 969 978
55. P.J. Campbell, S. Yachida, L.J. Mudie, and et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer Nature 467 2010 1109 1113
56. S.P. Shah, R.D. Morin, J. Khattra, and et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution Nature 461 2009 809 813
57. M. Cavo, P. Tacchetti, F. Patriarca, and et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 2010 2075 2085
58. S.V. Rajkumar, S. Jacobus, N.S. Callander, and et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 2010 29 37
59. J.L. Harousseau, M. Attal, H. Avet-Loiseau, and et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 2010 4621 4629
60. J.F. San Miguel, R. Schlag, N.K. Khuageva, and et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 2008 906 917
61. A. Palumbo, R. Hajek, M. Delforge, and et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma N Engl J Med 366 2012 1759 1769
62. P. Kapoor, S.V. Rajkumar, A. Dispenzieri, and et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis Leukemia 25 2011 689 696
63. F. Davies, and R. Baz Lenalidomide mode of action: linking bench and clinical findings Blood Rev 24 suppl 1 2010 S13 S19
64. K.C. Anderson New insights into therapeutic targets in myeloma Hematology Am Soc Hematol Educ Program 2011 2011 184 190
65. D. Chauhan, T. Hideshima, and K.C. Anderson Targeting proteasomes as therapy in multiple myeloma Adv Exp Med Biol 615 2008 251 260
66. S. Mukherjee, N. Raje, J.A. Schoonmaker, and et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice J Clin Invest 118 2008 491 504
67. G.J. Morgan, W.M. Gregory, F.E. Davies, and et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis Blood 119 2012 7 15
68. P.L. McCarthy, K. Owzar, C.C. Hofmeister, and et al. Lenalidomide after stem-cell transplantation for multiple myeloma N Engl J Med 366 2012 1770 1781
69. T. Facon, M.A. Dimopoulos, A. Dispenzieri, and et al. Initial phase 3 results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT) Blood 122 2013 2
70. P. Sonneveld, I.G. Schmidt-Wolf, B. van der Holt, and et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial J Clin Oncol 30 2012 2946 2955
71. M. Attal, V. Lauwers-Cances, G. Marit, and et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma N Engl J Med 366 2012 1782 1791
72. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
73. Y.N. Demchenko, O.K. Glebov, A. Zingone, J.J. Keats, P.L. Bergsagel, and W.M. Kuehl Classical and/or alternative NF-kappaB pathway activation in multiple myeloma Blood 115 2010 3541 3552
74. J.F. Rossi, J. Moreaux, D. Hose, and et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study Br J Cancer 101 2009 1051 1058
75. M. Andrulis, N. Lehners, D. Capper, and et al. Targeting the BRAF V600E mutation in multiple myeloma [published online April 23, 2013] Cancer Discov 3 2013 862 869
76. A. Brioli, F.E. Davies, W.M. Gregory, and et al. Low rate of second primary malignancies (SPMs) in newly diagnosed multiple myeloma (MM) patients treated with lenalidomide: first results from the MRC MM XI trial (18th Congress of the European Hematology Association, Stockholm, Sweden, June 13-16, 2013) Haematologica 98 suppl 1 2013 104 (P242)